Co-Authors
This is a "connection" page, showing publications co-authored by SCOTT ERIC WOODMAN and MICHAEL TETZLAFF.
Connection Strength
1.016
-
Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Hum Pathol. 2015 Aug; 46(8):1101-10.
Score: 0.134
-
Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma. Clin Cancer Res. 2023 01 04; 29(1):154-164.
Score: 0.057
-
Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2023 Jan; 613(7945):E3.
Score: 0.057
-
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2022 06; 606(7915):797-803.
Score: 0.055
-
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science. 2021 Dec 24; 374(6575):1632-1640.
Score: 0.053
-
Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma. Oncoimmunology. 2021; 10(1):1992880.
Score: 0.053
-
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med. 2021 08; 27(8):1432-1441.
Score: 0.052
-
A phase II study of the insulin-like growth factor type I receptor inhibitor IMC-A12 in patients with metastatic uveal melanoma. Melanoma Res. 2020 12; 30(6):574-579.
Score: 0.049
-
B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020 01; 577(7791):549-555.
Score: 0.047
-
Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 Dec; 24(12):1941.
Score: 0.043
-
Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 Dec; 24(12):1942.
Score: 0.043
-
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 11; 24(11):1649-1654.
Score: 0.043
-
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 02; 19(2):181-193.
Score: 0.041
-
Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med. 2017; 2.
Score: 0.038
-
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017 03 01; 9(379).
Score: 0.038
-
Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients. Cancer. 2017 04 15; 123(8):1372-1381.
Score: 0.037
-
Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med. 2016 10 25; 14(1):168.
Score: 0.037
-
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016 08; 6(8):827-37.
Score: 0.036
-
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology. 2016 Mar; 5(3):e1136044.
Score: 0.035
-
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016 Feb; 6(2):202-16.
Score: 0.035
-
Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol. 2015 Feb; 135(2):508-515.
Score: 0.032